Smoking and Tobacco News

The FDA announced that it has revoked its previous marketing denial orders to Juul Labs in part because of new case law and further review, according to a press release from the agency.

More adults with exclusive daily e-cigarette use receiving 8-week varenicline quit than those receiving placebo, according to a research letter published in American Journal of Preventive Medicine.

Secondhand cigarette smoke increases the risk for developing rheumatoid arthritis, but only in cases of low-level exposure, according to data published in Scientific Reports.

SAN DIEGO — After receiving educational texts on tobacco use disorder treatment for 13 days, physicians felt more confident treating this disorder, according to research presented at the American Thoracic Society International Conference.

A rheumatology clinic initiative to connect patients with smoking cessation resources was feasible, cost-effective and boosted referrals to the state quit line 20-fold, according to data published in Arthritis Care & Research.

People who vaped and smoked cigarettes appeared four times more likely to develop lung cancer compared with those who only smoked, according to study results presented at American Association for Cancer Research Annual Meeting.

Back in 2019, the CDC declared e-cigarette or vaping product use-associated lung injury an epidemic and later expressed confidence in the additive, vitamin E acetate, being strongly linked to this outbreak.

Following transplantation, recipients with a lung from a donor who had tobacco smoke exposure did not have higher mortality, according to results published in American Journal of Respiratory and Critical Care Medicine.

An offer to speak with a smoking cessation practitioner during a lung cancer screening appointment was accepted by a majority of current smokers, according to results published in European Respiratory Journal.

Cytisinicline was associated with a greater rate of nicotine-containing e-cigarette cessation compared with placebo during 12 weeks of treatment and up to 4 weeks posttreatment, according to results from the phase 2 ORCA-VI trial.